StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Pharmaceutical Sales — United States by Quarter

Pharmaceutical Sales — United States ($M) ($M)

QuarterlyAnnual

Merck Pharmaceutical Sales — United States: $8,827M in Q2 2026, up 6.0% from a year earlier.

Latest, Q2 2026
8,827
Period ended Jun 30, 2026
Change on a year earlier
+6.0%
8,328 in Q2 2025
History
40 quarters
Since Q1 2016
Sources
16
Documents cited below

Where the Q2 2026 figure comes from

“|| United States | 8,512 | 8,827 | 17,338 | 7,927 | 8,328 | 16,254 | 9,493 | 8,662 | 34,409 | 6 | 7”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — United States ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20268,827+6.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20268,512+7.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20258,662+12.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 20259,493+15.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 20258,328+12.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20257,927+14.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 20247,728+15.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20248,227+15.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20247,399+12.6%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q1 2024Mar 31, 20246,936+13.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 20236,698+14.1%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20237,153+8.1%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20236,570+14.7%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2023Mar 31, 20236,117-9.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 20225,871+1.4%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 20226,620+16.8%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up pharmaceutical Sales — United States

Cite this data

StockData. (2026). Merck Pharmaceutical Sales — United States ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.